Neostygmin in snake bite
Reading File
Finding Sources
Searching PubMed
neostigmine snakebite neurotoxicity
Searching the Web
neostigmine neostigmin snake bite clinical use mechanism antivenom
Reading File
Searching PubMed
neostigmine snakebite neurotoxic cobra
Reading Web Page
neostigmine snake bite mechanism dose evidence
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of neostigmine in snakebite management, drawn from multiple authoritative textbooks:
Neostigmine in Snakebite
Rationale / Mechanism
Snake venoms — particularly elapid venoms (cobras, kraits, coral snakes, mambas) — cause neurotoxic paralysis via two mechanisms:
| Toxin Type | Site of Action | Reversible? |
|---|---|---|
| Postsynaptic α-neurotoxins | Competitively block nicotinic ACh receptors at the NMJ | ✅ Yes — reversible |
| Presynaptic phospholipase A₂ neurotoxins | Destroy nerve terminals, prevent ACh release | ❌ No — irreversible |
Neostigmine is an acetylcholinesterase inhibitor — it prevents breakdown of acetylcholine in the synaptic cleft, increasing ACh availability to overcome competitive postsynaptic receptor blockade. This is analogous to the treatment of myasthenia gravis.
Key point: Neostigmine works only against postsynaptic neurotoxins (e.g., cobra/Naja species). It has little to no effect against presynaptic neurotoxins (e.g., Bungarus caeruleus — common krait, taipan). This is why it does not work uniformly for all neurotoxic snakes.
Indications
- Patients with objective evidence of neurotoxicity: ptosis, inability to maintain upward gaze, bulbar palsy, or limb weakness
- Primarily used for bites by postsynaptic toxin-producing elapids: cobras (Naja spp.), coral snakes (Micrurus spp.)
- Used as adjunctive therapy alongside antivenom — it is not a substitute for antivenom or airway management
Protocol (Harrison's Table 471-2)
Step 1 — Test dose (with atropine pretreatment):
| Drug | Adult Dose | Pediatric Dose |
|---|---|---|
| Atropine (pretreat first) | 0.6 mg IV | 0.02 mg/kg IV (min 0.1 mg) |
| Edrophonium (if available) | 10 mg IV | 0.25 mg/kg IV |
| — OR — | ||
| Neostigmine | 0.02 mg/kg IV or IM | 0.04 mg/kg IV or IM |
Step 2 — If objective improvement seen after 30 minutes, continue with:
| Drug | Adult Dose | Pediatric Dose | Frequency |
|---|---|---|---|
| Neostigmine | 0.5 mg IV/IM/SC | 0.01 mg/kg | Every 1 hour as needed |
| Atropine | 0.6 mg IV infusion over 8 h | 0.02 mg/kg over 8 h | Concurrent |
Goldman-Cecil Medicine gives a slightly different dosing reference: neostigmine 35 µg/kg IV, repeated up to every 1–3 hours, with a maximum of 140 µg/kg/24 hours.
Atropine is mandatory before each neostigmine dose to prevent muscarinic side effects: bradycardia, hypersalivation, bronchospasm, and excessive secretions.
Clinical Response & Limitations
- If the patient responds to the initial dose (reduced ptosis, improved swallowing), continued neostigmine is appropriate
- If there is no response, the neurotoxin is likely presynaptic — further neostigmine is unlikely to help
- Does NOT reverse established respiratory paralysis caused by presynaptic neurotoxins
- Not recommended as first-line or sole therapy in North American crotalid (pit viper) envenomations — antivenom remains the definitive treatment
- Evidence base is largely case reports and small case series — no large RCTs exist (LITFL/PubMed search confirms no recent systematic reviews)
Important Caveats
- Not a substitute for antivenom or mechanical ventilation — airway must always be secured if there is swallowing/breathing difficulty
- Ineffective for krait (Bungarus caeruleus) bites in clinical studies — presynaptic mechanism dominates
- Patients should be monitored in ICU for at least 24 hours
- Historical use since ~1950 (Brazil, Micrurus frontalis bites); Asiatic cobra case series reported improvement (Gold BS, Ann Emerg Med 1996)
Sources:
- Harrison's Principles of Internal Medicine 22E (2025), Table 471-2
- Goldman-Cecil Medicine, Neurotoxic Snakebite Treatment section
- Sabiston Textbook of Surgery, Elapid Envenomation chapter
This is a shared conversation. Sign in to Orris to start your own chat.